9/8 Dr Weldon Gilcrease: Colorectal Cancer - An Overview

Northern Medical Center Education Videos
2 followers
47 Video Views·Sep 13, 2026
Slides link:
https://drive.google.com/file/d/1htbW3w6pRLxkKEb8WXyE3Oz9Rwbs0uPf/view?usp=drive_link
AI Generated·May contain errors
Video Summary
AI GeneratedDr. Weldon Gilcrease provides a comprehensive overview of colorectal cancer, detailing epidemiology, staging, and treatment. He emphasizes the shift toward personalized medicine through immunotherapy for MSI-high patients, the efficacy of total neoadjuvant therapy for rectal cancer, and the critical role of structured exercise in reducing recurrence and mortality for stage 2 and 3 patients.
My name is Weldon Gilcrease. I'm a medical oncologist at the University of Utah,
and I've been here for 17 years. My talk really is an overview of colorectal cancer.
You guys have probably seen patients with colon or rectal cancer in Taiwan?
Yes.
I'm hoping that I'm at the right level. I run the fellowship here. In the United States,
we do internal medicine, and then if you want to subspecialize in oncology and hematology,
we do them both together. In Europe, they're separated, but here we do our training in
hematology, so leukemia, lymphoma, as well as benign hematology like thalassemia and clotting.
We do with oncology, and I run the fellowship here. I'm pretty involved in medical education,
but I don't want to talk too high. I also don't want to talk too low of a level.
If you already know all of this, you can tell me to move it along.
The learning objectives today are to talk about a basic understanding of staging of
colorectal cancer. I want to talk a little bit about how we define rectal cancer. When you get
below the peritoneal reflection, the colon becomes the rectum, and we treat these differently
because you lose that peritoneal sheath. There's a fibrous covering in the colon,
and then you lose that when it gets into the pelvis and becomes the rectum. So,
radiation really plays a role in earlier rectal cancer, and we'll talk a little bit about that.
Do you guys know what MMR and MSI-high colorectal cancer means, Joanne or Angel?
Is that related to heredity, family, disease, family?
Exactly. Very good. Very good. So, in Taiwan, and same with the United States,
one of the most common inheritable colon cancers is Lynch syndrome.
And so, MMR, you lose your mismatched repair proteins, or we also call it microsatellite
instability high. I'll talk a little bit about that. Just like you said, I think that was Angel
that said it, but just like you said, it's important because it means that we can use
immunotherapy. So, this is almost, I think of this as a completely different disease now.
We don't use a lot of the traditional chemotherapy, even sometimes surgery,
I think is a question of whether we need that because we have such excellent responses.
I wanted to talk a little bit about something called stage 4a colon cancer or rectal cancer,
which means it's only gone to one organ because one thing that's unique about colon cancer is
when it has traveled and metastasized to a single organ, it's still curable disease.
So, those are the main points I'm going to cover today. This is from a Taiwanese journal,
the Journal of Epidemiology and Global Health. So, this is Taiwanese data
showing that colon cancer is the fourth most common cancer. I have conflicting data about this.
There's been a decrease in liver cancer in Taiwan. So, liver cancer is no longer the third
leading cancer in terms of incidence and mortality. Do you guys know why there's
been a decrease in the incidence of liver cancer in Taiwan?
The HPV and is...
Very good. The vaccine.
Very good. You guys are on top of it. That's right. So, you've seen a decrease in liver cancer,
but there actually has been an increase in colon and rectal cancer. So,
this is some data that I just pulled from a Taiwanese website. And if you look at the
incidence, how many colon cancers and rectal cancers you see per year, this is 2021. It's
the third most common cancer, and it's the third most common cancer of cancer-related death
in Taiwan as well. So, my hope today was to give you guys a lecture and a talk on something that I
think is very common when you return back home. And you guys will do residency next. Is that
right? Internship and residency? Yes.
What... Joanne, what do you want to do?
I'm not sure what specialty I want to do because we still have one year rotation for other
specialties. So, some of specialty we haven't really seen yet.
Okay. That's fair enough. I didn't decide until pretty late. It's our fourth year of medical
school. But this, you guys, I think will come across this. So, I wanted to really hone in on
colon and rectal cancer. In Taiwan, just to point out, the earlier we catch the disease,
the more curable it is. So, in Taiwan, like the United States, you're seeing increased number of
patients that aren't just the Lynch syndrome patients. So, it's not just the familial disorder,
but more patients that are younger than 50 years old. So, this is an increasing
problem in younger patients. I know this from my own clinic. I have patients in their 20s and 30s.
I've had patients that are teenagers with colon and rectal cancer. So, this is a more common
thing that the best... I mean, of course, this is talking from a very surface human level,
but the best, I guess, explanation that I've heard is that this may be a change in the gut
microbiome, which is probably related to our lifestyle and our diet and a lot of other
factors like that. The screening in Taiwan is every person from age 45 to 74. If you have a
family history, it's 40 years old. And at least there, there are these fecal immunochemical tests
or the FIT test every two years. I also read in Taiwan that you can do colonoscopy, which is the
common screening in the United States, every 10 years. It takes about 10 years for a polyp or a
benign growth to turn into a cancer is what we think, especially the common left-sided cancers
in the sigmoid colon, the descending colon, and the rectum. This is from Taiwan as well. Cancer
is the leading cause of death in Taiwan in males. And so, this is really, I think, a large
burden of disease that we see. Do you guys learn the TNM staging? Is this something you guys have
heard about? Okay. Yes. Yeah. So, here, if you look at this cartoon diagram, can you see my arrow?
Yes. Yeah. Okay. So, basically, the way the T-stage or the tumor stage is the depth of
invasion into the wall of the colon or the rectum. And the deeper it goes into the wall,
the higher the T-stage. So, we have T1, T2, T3, T4, but you can still be a T4 where it's gone
all the way through the wall into the serosa and have no lymph nodes and still be a stage 2.
So, the overall staging, it can be a little confusing because you have T-staging, N-staging,
depending on how many lymph nodes are involved, and then metastasize or M-staging as well. So,
basically, stage 2 is no lymph nodes. Stage 3 is lymph nodes. It's pretty simple in colon
cancer, which is kind of nice. And I'm not going to go into more detail than that because I really
just don't think you need it. You know, for most of us, even myself, I think there are nuances when
I'm treating a patient, but those nuances aren't important for this kind of broad overall view.
So, T-stage, how deep does it go into the wall? It's not the size of it, although the size kind
of correlates with that, but it's the depth of invasion. Stage 2 is a T3 to T4. Stage 3, again,
lymph nodes are involved. And stage 4 is when it's metastasized far away. So, it's traveled usually
through the bloodstream to distant sites. Stage 4A means it's only gone to one organ, most commonly
the liver. Stage 4B would be it goes to two or more organs. So, for example, if it went to the
liver and went to the lungs, that would be a stage 4B. Are you guys familiar with this term peritoneal
and carcinomatosis? Is it spread in the peritoneum? Yes, exactly. So, on the surfaces of the abdominal
cavity. This now, probably about seven or eight years ago, this became its own stage because this
requires something called cytoreductive surgery, this large surgery where the peritoneal surfaces
are stripped of all the cancer. And that is now a standard practice when you, when patients only
have it in the peritoneum, which is often hard to see on a scan. You can see it in the operating room
and then you can often see it if the patient has quite a lot of ascites with a normal liver
function. So, if you have fluid and you're wondering why is that fluid there, that can be,
that can be the only sign that you have of peritoneal carcinomatosis. So, that's the basic
staging I was going to go through. And just as I said, the earlier the stage we find, this is why
screening I think is so important, the earlier stage, the more curable it is. And if you look
down here, stage one, over 90% of the time it's cured with just surgery alone. Stage two,
with surgery, sometimes chemotherapy, you get cure rates, this is old data, it's probably higher
than this, probably 80 to 90%. Stage three, depending on what stage three you are, this is
depending on how many lymph nodes are involved, you know, it can be curable in up to probably 75
to 85% of the patients. And stage four, this is still a curable disease. If you have a patient
with liver only cancer, colon cancer or rectal cancer that's metastasized only to the liver,
that can be curable in 40 to 50% of patients. So, stage four I think is a little bit tricky
because I don't think we lump them all together as the same patients. Here's just a very basic
slide of how we treat. So, stage one, surgery or resection alone. And sometimes that
resection is done endoscopically, so that the gastroenterologist will go in and basically
remove the tumor from the inside, but often it's a surgery. So, you get surgical resection.
Stage two, if it is a more aggressive stage two, we often add what's called adjuvant chemotherapy.
Angel, do you know the difference between adjuvant and neoadjuvant therapy?
Neoadjuvant is before the surgery. Very good. You guys are very good. Yeah,
that's exactly right. So, this is typically adjuvant chemotherapy. Stage three, the standard
is surgery followed by adjuvant chemotherapy. And then stage four, again, surgery in specific
circumstances, usually that's if it's gone to a single organ, so it's a stage four A, one organ.
And surgery is definitely something you should think about with those patients. Now, I would
say that all of this is for the MMR proficient, the non-immunotherapy colon cancers. So, in Taiwan,
the number of patients that have MSI high, microsatellite instability high, or mismatch repair
deficient, sorry, mismatch repair deficient tumors, it's about 7% or 8%. In the United States,
it's a little bit higher than that. It's probably about 10% to 12%. Yeah, okay. So, this is a really,
really busy slide, but I think the important thing that I was trying to show you here
is about chemotherapy. And chemotherapy is three to six months of 5FU-based therapy. Now, Taiwan,
and I feel like Southeast Asia, you guys use a lot of S1. You guys know what S1 is? It's an
oral chemotherapy. Okay, not so familiar here. Okay, good. That's fine. So, we use something
called fluorouracil. I'll talk a little bit more about this. The pill version of this is cape
cytabine. And we do three months or six months. It's most common, really, to do six months.
This is a trial from a couple of years ago that was looking at three months versus six months.
And I just wanted to show you these graphs because I think just seeing, do I do three months or six
months? And you can either do CAPOX, which is cape cytabine. This is the pill version.
And this is full FOX. This is 5FU plus oxaliplatin. Oxaliplatin is a chemotherapy,
I think that adds very little to the 5FU or cape cytabine. But the way that I usually think of this
is 80% of the work is being done by the 5FU or cape cytabine. And about 20% of the effectiveness
or efficacy is done by oxaliplatin. So, in patients with stage 2 that are high risk or
if they're stage 3, so they have lymph node involvement, surgery followed by chemotherapy,
three to six months, mostly with 5FU, often with the addition of oxaliplatin, will reduce the
recurrence sometimes with an absolute risk reduction of 15%. And if you have an absolute
risk reduction of 15%, what's the number needed to treat to prevent one recurrence
or even one death? So, remember, one divided by 15% is about six, right? Something like that,
six and a half. Okay. Sorry, this slide was so busy. I don't really like this slide,
but I want you to see that we're using CAPOX or full FOX. Sometimes you can do 5FU or cape
cytabine by themselves, but when they're added with oxaliplatin, it's two chemotherapies
together. Rectal cancer is important. I mentioned this at the beginning, you lose this peritoneal
sheath and we know that then cancer cells can kind of float into the peritoneum and because
of that, radiation has historically played a role in rectal cancer. Every year I practice,
it's interesting. I think that every trial is supposed to answer a question, but it often
asks more questions too. So even though over the years, when I was a medical student, I always felt
the more trials there were, the more you knew the trials, the more they would narrow down what you
do, but it's actually been the opposite. I find every trial that comes out, there's more ways to
think about it. There's more questions to be asked, but rectal cancer, I would say the standard in the
United States is what's called total neoadjuvant therapy. And like you said, Angel, neoadjuvant
means the operation comes at the very, very end. So it's called total neoadjuvant therapy.
That is a combination usually of five and a half weeks of radiation to the tumor and the area around
it. And then chemotherapy after that, usually we do about three months of chemotherapy and then
surgery at the very end. Now, I asked this question, why would we do neoadjuvant versus adjuvant? And
you know, I think that there are definitely advantages of neoadjuvant therapy. For example,
if you had a patient that went for surgery up front and there were a lot of complications,
so there were fistula and abscesses and surgical drains that are having to be left in,
it could be that you never get to a very effective treatment in the treatment of colon and rectal
cancer. And that is chemotherapy especially where it's one of the cancers that chemotherapy
is more active in the treatment of colon and rectal cancer. So you make sure the patient
gets the active therapy. You also, I think, select for diseases that are more aggressive,
like if it's going to grow right through chemotherapy or keep growing and start spreading,
that's a cancer that probably shouldn't have an operation because it's a very aggressive cancer.
So I think that's one of the advantages of doing neoadjuvant. You also get a chance
as the medical oncologist, which is what I do, I do the chemotherapy part, you get a chance to
see if it's effective against the cancer. If the cancer is out, you don't know if it's shrinking
the cancer or not. So just a couple of things. Yeah, the standard treatment for a stage 2 or
3 rectal cancer is typically total neoadjuvant therapy with radiation and chemo followed by
chemotherapy by itself. Oh, just a word on staging. If it has come out in surgery, we use pathologic
stage. So you'll see a PT3 or like if there's one or two lymph nodes involved, you'll see it
written as PN1. If you don't have a pathologic stage, like in rectal cancer, it hasn't been
surgically removed and you don't have an operation yet, you'll see us write clinical stage based on
imaging. Usually it's MRI of the pelvis to see the staging of a rectal cancer. MRI is not used
in colon cancer, but it's used in rectal cancer. Do you guys know what it's called if you have
a clinical stage or what the staging is if they've had neoadjuvant radiation, neoadjuvant
chemo, and then they have it surgically removed? I don't know. That's good. Okay. Yeah. So there'll
be a YP. So a Y and then a P means they've been treated and then that's the pathologic stage.
I wanted to share this with you because in stage 2 and 3 colon cancer and rectal cancer,
this was a study that just came out a little over a year ago. Have you guys heard about this
exercise after adjuvant chemotherapy and colon cancer? No. So this was a study that looked at
900 patients all over the world, mostly Canada and Australia. And they took 900 patients that
have had stage 3 colon cancer mostly. There were some stage 2, but they were mostly stage 3.
And they divided patients into structured exercise for 3 years. So you finish chemotherapy. A couple
months later, you started working with a physical therapist or a personal trainer. And then you had
exercise with a trainer for about 3 years. And you only met with a trainer about every 2 weeks
for the first 6 months. And then it was once a month for the next 2.5 years.
So this was really, really shocking to me how much exercise actually helped. So exercise,
if you were on the group that was doing exercise, the patients didn't lose weight. So there was no
weight drop between the 2 patient groups. The first group got a handout. So got a bunch of
papers saying this is how to exercise, this is how to eat well, this is how to live well
after a colon cancer diagnosis. The second group got those handouts, but they also had
structured exercise. So they exercised again with a physical therapist.
If you look, there was an improvement both in mortality and the relapse group. So they called
it health education group, I can't see my slide up here, but versus structured exercise or the
exercise group. So the exercise group did better in terms of mortality and in terms of less relapses,
especially in the liver. If you look at the patients that were exercising, half of them
compared to the other group had relapse in the liver. They also had much less new cancers or
different cancers over the time that they were observed. So one of the things for me, you know,
is this is hard evidence from a prospective randomized trial that exercise can actually
improve outcomes in colon and rectal cancer. The other thing that I often get asked by patients
is, well, what can we do to increase or decrease our chances that this will come back? And patients
often feel, I think one of the things that cancer does to people is it takes the feeling of control
out of their hands. So they want to have some kind of control over something. And they often ask me
about diet. We don't have any evidence as far as I know, in terms of prospective large evidence that
has shown that diet can decrease your chance that cancer will come back or that you will die of a
cancer that's already been diagnosed. But we do have hard evidence now that exercise can do that.
So this was, I don't really go into the weeds of this trial. I think it's a very interesting
trial. I think it's a very important trial. But basically they did something called 10 metabolic
equivalence of tasks or 10 METs per week over what their baseline was, which is basically about
two and a half hours of brisk walking per week over what they were doing at baseline. So this
was very compelling evidence. And I wanted you guys to have heard about this trial called the
challenge trial published last year in the New England Journal of Medicine.
Here's my slide or a couple of slides on mismatch repair deficient colorectal cancer.
So most of them are associated with Lynch syndrome, but not all of them. They can also
be sporadic, meaning it's not a familial disease, but you can still be MMR deficient, which is about
50-50. You'll see the terminology proficient MMR. These are the normal, this is the, in Taiwan,
this is the 92% of colon cancer. The 8% are deficient mismatch repair tumors. They're
mostly on the right side in the ascending colon. It's where we see them more commonly,
but not all the time. It's the four mismatch repair proteins are MLH1, PMS2, MSH2, and MSH6.
This is immunohistochemistry showing brown means the proteins there and this light blue,
you can see that the proteins are lost in MLH1 and PMS2, which comes from a loss of MLH1.
That can either be because you obtained a mutated copy from your mother or father,
as we see in Lynch syndrome. This can also be because you have epigenetic regulation where you
have the promoter can be silenced by methylation of the cytosine in the promoter, which is also
a common way that you shut off MLH1 through epigenetic means. So this, I just want you to
have heard of mismatch repair, which is also associated like 98% of the time it's correlated
with something called microsatellite instability. Do you guys know what microsatellites are?
Yes. It's a thing inside the cell. I don't know how to describe it.
Yeah. It's in the DNA and you have these microsatellites, you have these places in the DNA
that aren't coded, but they have two to six nucleotide repeats. So for example, you could
have CGA, CGA, CGA, CGA, CGA. And those are usually the same size in every single cell that
the body makes. Every single cell in the colon, it'll be the same size of a microsatellite.
If you're missing one of these DNA mismatch repair proteins, those sizes start to vary.
For example, you can see, I'm trying to show you here, these are sizes based on sequencing of the
microsatellites in the DNA. And here, this is normal. But down here, you can see there's a
couple of different sizes of the same microsatellites. So this is what we call
microsatellite instability, which is tightly related to mismatch repair proteins being gone.
Now, why is it so different? Well, you can imagine if you're not fixing DNA appropriately,
not only can these microsatellites get to be different sizes, but within an exon where the
gene will be expressed, you can have the exons have mutations in them that lead to new proteins
that aren't typically there, which we call neoantigens. And we know this happens in colon
cancer that's mismatch repair deficient. These neoantigens, they can stimulate the immune system.
The immune system can see them as something that shouldn't be there, rather than a lot of the
proteins that are made in a cancer that are normal proteins in the patient's body. So the
immune system is harder to engage and attack. Now, you can see what happens here in a tumor cell,
right? In a tumor cell that has a neoantigen, a protein that's not usually there,
a lot of times what happens is a cytotoxic T-cell, so this is a CD8 positive cytotoxic T-cell,
will try to kill the tumor cell, but is blocked in doing so by programmed cell death ligand one,
which is the ligand and the receptor on the T-cell, which is programmed cell death one. So
the ligand and the receptor, this hides essentially the tumor from the T-cell. If I block this,
I think one of you mentioned immunotherapy. So if I use immunotherapy and I block this from happening,
then the T-cell can start to kill the tumor cell. So this was really groundbreaking, I think,
15 years ago or so in colon cancer when we realized that these MMR deficient tumors
respond very well to checkpoint inhibitors. This shows you that you can use PD-1, anti-PD-L1.
There's also another blocker in here called CTLA-4 and I think it's B80 and B86, but there
are a couple of different ligands for CTLA-4. But this is how I think of it. I think this is
video game, but this is supposed to be a shield, a cloak shield hiding the tumor from the rest of
the body. So what happens is tumors have a good way with the T-cell of trying to make sure we
don't have too much autoimmunity. So there's this system in place that blocks a T-cell from engaging.
This is the major histocompatibility complex one or HLA. It blocks this interaction from happening,
but then if you have a blocker to the blocker, you remove the shield.
Does that make sense? So that's what we call immunotherapy or checkpoint inhibitors. You'll
see them called ICIs, immune checkpoint inhibitors. Here's a list of them, but it's
really not that important. One of them that's been looked at in colon cancer and rectal cancer,
this is a study that came out last year, last summer as well, where they gave patients
with early stage, so most of these are stage three or stage two, rectal cancer and colon
cancer and they gave them six months. These are MMR deficient patients that got six months of
a PD-1 inhibitor, Dostarlimab, and this shows that each of these bars is a patient,
and if they go all the way to the top, it means their tumors completely disappeared.
So you can see all 50 rectal cancer patients, their tumors completely disappeared with immunotherapy
if they were MMR deficient. In Taiwan, this is going to be about one or two percent of patients.
In Taiwan, about eight percent of patients are going to be in these colon cancer patients,
and this is, again, these were patients that had resectable disease, so these could have been cut
out surgically, but instead they gave them immunotherapy for six months, and in colon
cancer, 82 percent of the time the cancer disappeared without needing surgery. So that's
why I just wanted to highlight that this is really a different cancer type. MMR deficient
colon cancer, eight percent of the time when you're in Taiwan and you're seeing a patient
with colon cancer, they're going to be MMR deficient. You should just try to remember
in the back of your mind, oh, I remember somebody told me that this is a different cancer. They
should be thought of differently, the treatments are different, the sequences are different,
and I think that's an important factor. I'll kind of move quickly here. I know I think I'm
supposed to end in seven minutes, but I wanted to talk a little bit about a trial. This came out two
years ago, that basically if you have stage 4A from colon to the liver, and you're proficient
MMR, so this is not deficient MMR, this is proficient MMR. They looked at liver transplantation
in, it was like 96 patients in this transmit data, and they showed that survival at five years if
you had a liver transplant was approaching 75 percent versus what we saw in the normal population
of an incurable stage 4 colon or rectal cancer, where survival is usually less than 10 percent.
Okay, so I think that, you know, I think that it's important to recognize a couple of things
in colon and rectal cancer, especially, you know, in the broad overview. If you're deficient MMR
or DMMR, if you're sensitive to immunotherapy or the immune checkpoint inhibitors, you should
really think about those patients differently. If you're a stage 4, but you've only gone to one
organ, which is most commonly the liver, you should think of those patients differently.
You should really be thinking, is there a way that we could potentially cure these patients or get
rid of the cancer that spread to the liver? This was the, these here are the 90, I guess this is
94 patients. They were assigned to either transplant or chemo alone, and essentially what we saw was
this 73 percent of, and this was the, per protocol, was 73 percent versus 9.3 percent.
Some of the other, you know, some of the other new things that we're seeing,
did you guys hear all the news about daroxonracid in pancreatic cancer? There's a new way that we
can, KRAS mutations in colon cancer are actually 40 percent, but at G12c, it's about 3 percent
of colon cancer. We have medications for this that can block it. We have pretty good, not great,
but pretty good medications for BRAF D600E. So some of the genetic subtypes of colon cancer,
this is about 10 percent. This can be associated with deficient MMR, but when it's associated with
the non-deficient MMR, so the proficient MMR, this is a very aggressive disease.
And then we mentioned a little bit about when it's spread to the peritoneum,
which historically these patients did the worst. If you look, here's an old paper that I like to
show that shows that the top line, this is survival. See, these are Kaplan-Meier curves
of patients with stage 4 colon or rectal cancer to only one organ. If it's lung, they do the best.
If it's peritoneum, they do the worst. And then it's the middle road if they have liver only. So
they're kind of in between the two. So yeah, I want to just talk a little bit about 5-FU because
and again, I think Taiwan uses quite a bit of S1. This is their anti-folate or anti-folate
synthesis drug. But we have, the one that we use in the United States is either 5-FU
or capecitabine. That's a pill version that becomes 5-FU. And then 5-FU blocks this protein
called simodilate synthase. We usually give lucavorin to help it work better actually.
So we often will give folate or folinic acid along with 5-FU or capecitabine.
But it's basically blocking one of the only ways that we get thymidine monomers
for DNA production. So you go from uridine to thymidine through thymidilate synthase.
So just a word on 5-FU, capecitabine. Oxaliplatin is the other chemotherapy that we often use. I
these are all approved in Taiwan as well. So I think all of these are used. But again,
at least in Japan and Korea, I believe they use a lot of S1 and I've never given S1 and it's not
even on our formula here. So just to kind of summarize here in these last couple of minutes,
understand the staging. Remember that there's a T and M stage. T is the depth of invasion.
If it's gone to a T3, which is most common, it's a stage 2. There's no lymph node involvement.
If you have lymph nodes that are involved but it hasn't spread farther away, it's stage 3.
Remember that the treatment for colon cancer is remove it in stage 2 and 3 and then give
adjuvant chemotherapy. And then total neoadjuvant therapy with radiation, chemotherapy. Chemotherapy
alone followed by surgery. And remember that exercise for 3 years after you finish all that
treatment in these patients actually decrease your chance the cancer will come back and decrease
cancer-related mortality. Just understand if you can remember, it sounds like you guys already knew
this before this talk, but remember that 8% of patients in Taiwan will have deficient MMR
and those patients should really be thought of how do we use the checkpoint inhibitors.
If you have a stage 4A colon cancer, it's still curable if it's surgically removable.
And then I talked a little bit about transplant even. If you had 25 spots in the liver that
isn't surgically removable, but we are now in the United States thinking of transplant in those
patients. And then 5 a few capecitabine are really the mainstay, so I just wanted you to see how
they work. I'll stop there. And if you guys have any questions, I mean, questions about this,
questions about what I do, any questions? Can I ask what's the most differences you've seen
in the treatment of the colon cancer between Taiwan and the United States?
It looked very similar to me. That's a good question. I think I read something
from a Taiwanese website and they follow the NCCN guidelines. So the NCCN is the National
Comprehensive Cancer Network. The center I'm at, we're part of that group, so I'm on one of the
guidelines. I'm not on the colon and rectal cancer guidelines, but they follow those guidelines. So
I think it's very, very similar. Let me look up to see does Taiwan use S1?
No, they don't. So I think it's very similar to what we do here. Fulfox, Kapox, Fulfuri,
even Pembrolizumab, Dostrolimab, Novolumab, a lot of the same immunotherapies, a lot of the same.
I know I saw one of their formularies and it looked like it was almost identical to the U.S.
Are either of you thinking you're going to be more on the surgical side or don't,
procedural side or don't go there? I think when we go to our hospitals,
surgery, colon surgery, and for the rotation, and I think they're mostly more, more,
more do the surgery sites because if you need the chemotherapy or radiation, they will just
refer, and often they can also follow up in the total rectal surgery. That's, that's, that's okay.
But I think most, mostly I was learning is the surgery, how can they do, and which,
which kind of person, which kind of patient that needs surgery. Yes. I think when I,
when doing my rotation, I learned that more. Okay. Yeah. Yeah. I, I, I, but I do, I do think
the algorithm, like how all those patients are treated, like if you're, you know, the most common
you're going to see as a proficient MMR stage three colon cancer, and those patients usually
get it removed and then see the medical oncologist for, for adjuvant chemotherapy. So I, you know,
which is either 5-FU capecidabine or full Fox capox. So it's, it's, it, you know, I didn't want
to give you guys to get you guys too much into the weeds, but it's such, it looks like it's such a
common cancer and a rising cancer in Taiwan that I thought it was really important. You guys just
kind of have a lecture on it and think about it a little bit. The exercise part is really
interesting. I mean, to me, this is starting to get at, you know, what can we be doing? I, I,
you guys may have seen the Falun Gong. There was a, there was a paper it's now probably 10 years
old, but it was just an observational paper showing that patients with metastatic cancer,
when they match them had a much longer survival in the Falun Gong population. So I still think
there's, there's, there's quite a, you know, ways we need to go. Like they, we don't really understand
why exercise had such a profound improvement. But I, you know, it's funny for years, I was telling
patients, I don't think diet has as much of an impact as exercise, being active. And it was nice
to have a paper, that challenge paper was the name of the trial, but the challenge, the challenge
data was really impressive. Can I ask why a teacher you think diet is less important than exercise
because of the study, the study results or there are other reasons?
Um, yeah, I, it's interesting, right? It's like, I, because I seen the rectal cancer and the colon
cancer, they are more related to the diet. Oh, like the GI tract. Yeah, GI tract, what, what,
why, when they are happening because our diet is not good, that kind of thing. Yeah.
It's a, it's a good question. You know, I, I, I, but I, I also feel like I, I, I don't know this
for sure, but I feel like the gut microbiome is really impacted by activity. And if you look at,
you know, if you look at activity, you look at, you know, you, you, you even look at,
I mean, beyond just the surface, right? Like you look at, I know there's also been
Falun Gong studies where they looked at, um, the immune, the immune milieu, what are the
immune cells that are activated and, and, and down, um, which is again, just a surface way of
trying to understand what's happening. And I know Jinguan talks a lot about the ACEs. You guys have
probably had a lecture, lecture on that. We're talking about anatomy, chemistry, energy,
spirituality, but you know, which I think is a good way to, to, to think of it. But, but I, I,
so to go back to exercise, like why does exercise, where's that impacting the ACEs? I mean, is it,
is it doing something different energetically or is it, is it, it certainly it's chemically
changing things. I mean, the, the body's chemistry changes. We know, I remember when I was a fellow
about 16, 17 years ago, um, there was a study that came out from what the biggest cancer center in
the United States, which is, which is in Texas. And they took women with breast cancer who were
going to undergo surgery, but that have had a biopsy. They looked at the biopsy and they looked
at the immune profile of the biopsy. And then the surgery was going to be in like a month and they
randomized the women into like yoga, a change in diet. And then there was one that was just
exercise. The only one that had a real change and what that, what immune cells were up and down and
the immune profile looked like was the exercise group. So I don't, I think we, I think there's
still just a ton, just a ton we don't understand. Um, as you know, as, as you guys know, like,
you know, it's, it's like science, even though, you know, for me, this is my opinion more now,
but I think the fact that medicine took on the path of science, you know, and, and, uh,
I mean, for the most part, atheism and Darwinism and all, all this stuff, I think it, I think it
has kind of boxed in our ability to see more widely. So, so to look at exercise and say,
why is exercise doing that? And it's also, you know, it's also a statement about where we are
as a medical system, because as a medical system in the United States, the pharmaceutical companies
want to get a new drug. That's a billion dollars. Whereas exercise, right? Exercise, the cost of
what they did in that trial for three years, each year was about $3,500 per year to do,
to do exercise, to go running or, you know, do a brisk walking with a physical therapist.
They actually, there was just a publication about a month ago that showed that it was
cost beneficial for the exercise group. But I can tell you in my practice, insurance companies
aren't paying for exercise. They'll pay for a 50,000, $40,000 a month drug, but the $3,500 per
year exercise that they won't pay for. So it's, it's a, it's a, it's a, it's an interesting system
that we're in. I think they want to, want the cost down, don't, don't, don't, no matter the,
it's the exercise or the, or the drug is, if like this, if it's, if it's efficiency and they will
take it. So they don't think exercise is efficiency. Yeah. It's, it's, it's interesting.
It's yeah. I mean, it's the hard thing. So I showed you the slide of Taiwan where the number
one, the number one cause of death in Taiwan for men is cancer. Right. And, and so it's,
it's a huge money. You know, like there's a lot of money that's being passed around.
But it, it, you know, it's, it's so, so I think with, with that much investment and that much,
that much money in it, it gets hard to just put that aside and say what actually works.
And if exercise works, we should be paying for it. Right. I know there were, there were a lot
of jokes when that trial came out last year about X, the challenge trial by exercise. There were a
lot of people joking that if they had called it exercise a map. So if they had called it something
that sounds like a drug, where it's just exercise, people would have paid for it. I mean, people
would have paid a lot because I, I didn't go into this, but exercise actually did better
than the addition of oxaliplatin the chemotherapy. So we used to only use five a few. And when we
looked at full Fox, the addition of oxaliplatin, the benefit was less than the benefit that we
saw with exercise. So yeah, it's just a really, it's a fascinating, fascinating time. And you,
you guys are at the, about to start this career and, you know, watch all of this unfold.
Any other questions? I mean, any, any comments do you guys, was this too simple or too detailed
just so for me to try to do better in the future? It's very good to let her to remember those
things. Not too much or it's appropriate. Okay. Okay. So, so I, okay. So I don't need to put
more detail and I don't also don't need to put less detail. I think it's okay for us to
understand. Okay. We can learn, learn something and not feeling overwhelmed. Okay. Okay.
The effect of the exercise over, also we found other kinds of cancer.
That's a great, that's a great, great question. That, that, that I think is one of the most
important questions about this study. My, I'm only speculating. So I'm only guessing
because it hasn't been looked at to that extent in other cancers, but I see no reason why you
wouldn't see the same effect. I don't think there's anything special about colon cancer
that exercise would decrease the risk of mortality and the risk of relapse that would
be different from esophagus cancer, liver cancer, gastric cancer, breast cancer. I don't think there
would be any difference. So my, my guess would be, this is something that, that, that is probably
true for all patients that have surgically removed cancer and that there's nothing special
about colon and rectal. Well, Angel, Joanne, nice that I, you know, I, it's so hard to get out to
Middletown, but it's, it's, you know, good to connect with you guys there. All right. Well,
thank you so much. I'll send my slides. Yeah. Take care.
